 | |
| Vaccine description | |
|---|---|
| Target | Ebola virus |
| Vaccine type | Recombinant vector |
| Identifiers | |
| ChemSpider |
|
cAd3-ZEBOV (also known as the NIAID/GSK Ebola vaccine or cAd3-EBO Z) was an experimental vaccine for two ebolaviruses, Ebola virus and Sudan virus, developed by scientists at GlaxoSmithKline (GSK) and tested by National Institute of Allergy and Infectious Disease (NIAID).[1] This vaccine is derived from a chimpanzee adenovirus, Chimp Adenovirus type 3 (ChAd3), genetically engineered to express glycoproteins from the Zaire and Sudan species of ebolavirus to provoke an immune response against them. Simultaneous phase 1 trials of this vaccine commenced in September 2014, being administered to volunteers in Oxford and Bethesda.[2] During October the vaccine is being administered to a further group of volunteers in Mali. If this phase is completed successfully, the vaccine will be fast tracked for use in the Ebola virus epidemic in West Africa. In preparation for this, GSK is preparing a stockpile of 10,000 doses.[3][4]
- ^ Pavot V (December 2016). "Ebola virus vaccines: Where do we stand?". Clinical Immunology. 173: 44–49. doi:10.1016/j.clim.2016.10.016. PMID 27910805.
- ^ "Experimental Ebola Vaccine Processed in Maryland". Drug Discov. Dev. Associated Press. 2 October 2014.
- ^ "First British volunteer injected with trial Ebola vaccine in Oxford". Guardian. 17 September 2014. Archived from the original on 17 September 2014. Retrieved 17 September 2014.
- ^ "An Ebola vaccine was given to 10 volunteers, and there are 'no red flags' yet". Washington Post. 16 September 2014. Archived from the original on 20 February 2020. Retrieved 17 September 2014.